Research Article
Flow Cytometric Analysis of T, B, and NK Cells Antigens in Patients with Mycosis Fungoides
Table 4
The mean value of all cell surface antigens according to histopathological stage.
| | Histopathological stage | Patch | Plaque | Tumor | value | | 101 | 50 | 12 |
| | T cells surface antigens | | CD3+ | | | | 0.000↑ | | Mean ± SD | 71.26 ± 7.72 | 75.16 ± 9.12 | 88.90 ± 7.68 | | | Median; min.–max. | 71.50; 51.30–89.10 | 76.30; 48.70–92.20 | 88.80; 75.40–98.70 | | | CD4+ | | | | 0.000↑ | | Mean ± SD | 44.56 ± 8.32 | 47.22 ± 12.03 | 77.76 ± 15.58 | | | Median; min.–max. | 44.50; 28.30–73.60 | 47.60; 20.60–66.20 | 79.60; 55.50–97.50 | | | CD8+ | | | | 0.016↓ | | Mean ± SD | 24.24 ± 9.32 | 25.99 ± 10.52 | 7.98 ± 8.56 | | | Median; min.–max. | 22.25; 9.40–73.30 | 24.75; 11.40–66.30 | 3.80; 0.50–22.50 | | | CD4+/CD8+ | | | | 0.005↑ | | Mean ± SD | 2.18 ± 1.16 | 2.89 ± 5.23 | 43.41 ± 55.33 | | | Median; min.–max. | 1.90; 0.20–7.80 | 1.80; 0.30–35.30 | 19.20; 2.50–183.20 | | | TCRαβ+ | | | | 0.000↑ | | Mean ± SD | 66.63 ± 8.14 | 69.26 ± 8.22 | 86.39 ± 8.43 | | | Median; min.–max. | 67.70; 46.10–87.10 | 69.25; 45.80–86.50 | 85.10; 73.80–98.0 | | | TCRγδ+ | | | | 0.006↓ | | Mean ± SD | 4.35 ± 2.97 | 4.26 ± 2.75 | 1.28 ± 4.43 | | | Median; min.–max. | 3.60; 0.60–13.60 | 3.35; 0.50–11.20 | 1.20; 0.10–10.0 | | | CD7+ | | | | 0.044↓ | | Mean ± SD | 76.68 ± 10.28 | 71.99 ± 9.32 | 73.05 ± 27.14 | | | Median; min.–max. | 78.15; 2.80–93.10 | 72.20; 44.50–87.0 | 73.60; 11.70–98.0 | | | CD4+CD7+ | | | | 0.003↑ | | Mean ± SD | 38.91 ± 8.48 | 35.89 ± 8.22 | 51.34 ± 27.20 | | | Median; min.–max. | 9.65; 13.40–54.50 | 35.3; 16.0–53.10 | 48.70; 9.60–96.50 | | | CD4+CD7- | | | | 0.000↑ | | Mean ± SD | 7.10 ± 6.76 | 10.17 ± 7.94 | 27.70 ± 28.06 | | | Median; min.–max. | 5.0; 1.0–51.30 | 7.40; 2.20–35.90 | 20.80; 0.50–88.90 | | | CD71+ | | | | 0.000↑ | | Mean ± SD | 4.47 ± 7.77 | 3.94 ± 4.66 | 22.21 ± 21.28 | | | Median; min.–max. | 2.60; 0.10–71.0 | 2.40; 0.30–23.1 | 13.20; 3.60–57.70 | |
| | B cells surface antigens | | HLA-DR+ | | | | 0.000↓ | | Mean ± SD | 31.10 ± 9.76 | 32.49 ± 7.39 | 17.69 ± 12.73 | | | Median; min.–max. | 28.45; 11.40–60.20 | 31.80; 18.80–50.40 | 16.30; 2.20–43.70 | | | CD19+ | | | | 0.020↓ | | Mean ± SD | 11.55 ± 4.74 | 12.84 ± 4.44 | 8.11 ± 5.29 | | | Median; min.–max. | 11.40; 1.50–24.80 | 12.75; 4.70–22.50 | 10.0; 15.70 | | | HLA-DR+CD19+ | | | | 0.041↓ | | Mean ± SD | 10.79 ± 4.65 | 11.87 ± 4.36 | 6.80 ± 5.86 | | | Median; min.–max. | 10.65; 1.20–24.70 | 11.95; 2.90–20.50 | 7.80; 0.30–15.50 | |
| | NKT cells surface antigens | | CD3+CD16+CD56+ | | | | 0.000↓ | | Mean ± SD | 3.38 ± 3.46 | 3.61 ± 3.01 | 1.60 ± 1.86 | | | Median; min.–max. | 2.10; 0.20–20.50 | 2.55; 0.50–12.30 | 0.90; 0.20–6.20 | |
| | NK cells surface antigens | | CD3−CD16+CD56+ | | | | 0.000↓ | | Mean ± SD | 14.82 ± 8.14 | 11.73 ± 6.30 | 2.20 ± 2.35 | | | Median; min.–max. | 14.40; 2.60–39.80 | 11.50; 2.10–35.80 | 1.50; 0.10–8.0 | |
|
|
↓: decreasing with stage; ↑: increasing with stage.
|
